Orexin B

What Orexin B is, structurally

Orexin B is a peptide of twenty-eight residues, and the product page describes it as linear, in explicit contrast with Orexin A, which is folded and holds two disulfide bridges. That contrast is the most useful thing to know about handling this compound, because almost everything that dominates the other peptide's care is simply absent here.

The formula supports the description. There is one sulfur, and one sulfur cannot form an intramolecular disulfide, which requires two. The deposited structure for this CAS settles what that single atom is: it shows a methionine thioether, with no disulfide bond and no free thiol anywhere in the molecule.

That single fact removes a great deal. There is no cross-link to reduce, so reducing agents are not the hazard they are on the folded peptide. There is no scrambling risk, so the isomeric failure that a mass check cannot detect does not arise. There is no free thiol, so no oxidative dimerisation. What remains is the ordinary methionine liability: oxidation to the sulfoxide, adding sixteen units.

The composition is the other half of the picture, and it runs opposite to most peptides of this length. Of forty-four nitrogens, twenty-eight are backbone amides, leaving roughly fifteen or sixteen on side chains. Of thirty-five oxygens, twenty-eight or twenty-nine belong to the backbone, leaving only six or seven. Fifteen side-chain nitrogens against six side-chain oxygens is a strongly basic composition: abundant basic side chains, very few acidic ones.

That inverts the usual dissolution advice in a way worth being deliberate about. A basic peptide carries net positive charge at neutral pH and has a high isoelectric point, so lowering the pH increases its charge and its solubility. Where an acidic peptide is driven toward precipitation by a drop of dilute acetic acid, this one is helped by it.

Reconstitution and handling

Sterile water is the default solvent. Where a vial dissolves reluctantly, mildly acidic conditions are the right escalation here rather than the wrong one, for the reason above, and dilute acetic acid is the conventional choice.

Add diluent slowly down the inside wall of the vial, swirl gently, and let the solution clarify. Do not vortex; it introduces foam without dissolving anything faster.

No reducing agent is needed, since there is no disulfide for one to act on.

Adsorption deserves particular attention on a basic peptide. A net positive molecule binds readily to ordinary borosilicate glass, whose surface is negatively charged, so glass is a poorer choice here than it would be for an acidic peptide, and low-protein-binding polypropylene is the better default.

This is laboratory preparation chemistry, not dosing, administration, or protocol guidance of any kind.

Storage and stability

Store the lyophilized powder at -20 degrees C, sealed, desiccated and protected from light, and let a cold vial warm before opening. Reconstituted, hold at 2 to 8 degrees C, or aliquot and freeze rather than thawing repeatedly. A linear peptide has no fold to lose, so freeze-thaw is less damaging here than on the folded counterpart, though it remains worth limiting.

Methionine oxidation is the named liability. Air exposure, warmth and light all accelerate it, and the product is sixteen units heavier, which mass spectrometry resolves cleanly at this size. A sealed, cold, dark vial is the control.

The low side-chain oxygen count means comparatively few acidic and hydroxyl residues, which limits though does not eliminate the hydrolytic routes. Without a sequence on file this page will not name positions for deamidation or aspartyl isomerisation.

These are storage conditions for the material, not dosing or administration guidance.

How Orexin B is tested

Reversed-phase HPLC establishes chromatographic purity as area percent. A basic, highly charged peptide retains weakly on a standard C18 column, so high-aqueous starting conditions or an ion-pairing mobile phase should be expected, and trifluoroacetic acid in the mobile phase serves that purpose as well as improving peak shape.

Area percent is a chromatographic measure and not peptide content by weight. Solid-phase synthesis delivers a salt, and on a strongly basic peptide the counter-ion is a substantial proportional share of the vial contents.

Mass spectrometry confirms identity against 2899.30. A result sixteen units high indicates the methionine sulfoxide. Unlike the folded counterpart, there is no disulfide state to establish and no reduced-versus-oxidised comparison to run, so the identity check here is the straightforward one.

These describe general methodology, not a claim about any particular batch.

Handling FAQ

Is this the same compound as Orexin A? No. They are separate products. Orexin A is thirty-three residues, folded, with two internal disulfide bridges; this is twenty-eight residues and linear. The masses differ by well over six hundred units, so the two are not readily confused on analysis.

The vial is slow to dissolve. Does adding acid help? Here, yes. The composition is strongly basic, so the isoelectric point is high and lowering the pH increases net charge and solubility. This is the opposite of the correct answer for an acidic peptide, where acid drives the solution toward minimum solubility.

Full specifications for Orexin B.